Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Suceagu – page 30

447 clinical trials in Suceagu, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Suceagu at a glance
447
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

447 trials in Suceagu

Open in trial search

Chronic hepatitis B+1

Not recruiting

Study on Safety and Efficacy of Bepirovirsen and Drug Combination for Chronic Hepatitis B in Patients on Nucleos(t)ide Analogue Therapy

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:Bepirovirsen
  • Sponsor:GlaxoSmithKline Biologicals

Bladder cancer

Not recruiting

Study Comparing TAR-200 and Chemotherapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer After BCG Treatment

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Janssen Cilag International

Breast cancer

Not recruiting

Study of Trastuzumab Deruxtecan with or without Pertuzumab for Patients with HER2-positive Metastatic Breast Cancer

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AstraZeneca AB

Study of Secukinumab for Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Study to Compare Fianlimab and Cemiplimab Combination with Cemiplimab Alone for Adults with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study on Tiragolumab and Atezolizumab for Patients with Resected Stage IIB-IIIB Non-Small Cell Lung Cancer After Chemotherapy

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study of Alectinib and Platinum-Based Chemotherapy for Patients with Resected Stage Ib to IIIa ALK-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Study of Selpercatinib for Patients with Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer After Local Treatment

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Selpercatinib
  • Sponsor:Eli Lilly & Co.

Study of mRNA-4157 and Pembrolizumab for Patients with Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Pirtobrutinib to Bendamustine and Rituximab for Untreated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Loxo Oncology Inc.

Study of Tarlatamab for Patients with Limited-Stage Small-Cell Lung Cancer After Chemoradiotherapy

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Amgen Inc.

Study of BMS-986012, carboplatin, etoposide and nivolumab combination as first treatment for patients with extensive-stage small cell lung cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Atigotatug
  • Sponsor:Bristol Myers Squibb International Corporation

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Suceagu

What the registry says about research in the country

01 Female Urogenital Diseases and Pregnancy Complications

In Suceagu, clinical research in female urogenital diseases is focused on improving care for stress urinary incontinence. The trials are looking at whether new treatment approaches can better reduce symptoms and support daily comfort for women living with this condition.

  • Stress urinary incontinence
  • Female urogenital health
  • Symptom control and quality of life
  • Evaluating a new therapy approach

This area reflects a practical effort to find more effective options for a common and often disruptive condition.

02 Neoplasms

Cancer research in this city includes studies in non-small cell lung cancer, with attention on patients who have HER2 mutations. The work is aimed at determining whether a targeted treatment can improve outcomes compared with standard care after surgery.

  • Non-small cell lung cancer
  • HER2-mutated tumors
  • Post-surgical cancer care
  • Testing treatment effectiveness

This field highlights efforts to advance more precise cancer treatment strategies and strengthen long-term disease control.

03 Metabolic and Urologic Symptom Research

Another active focus combines obesity or overweight with urinary incontinence, reflecting interest in how weight-related health issues may affect urinary symptoms. The research is designed to see whether a new therapy can better improve patient-reported outcomes.

  • Obesity and overweight
  • Urinary incontinence
  • Women’s health
  • Improving symptom outcomes

These studies bring together metabolic and urologic care in a way that may help guide more personalized treatment.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.